In:
Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 10, No. 2 ( 2014-06)
Abstract:
To investigate the feasibility and efficacy of cyclophosphamide ( CTX )‐hydroxycamptothecin ( HCPT ) as second‐line chemotherapy on advanced E wing's sarcoma. Methods From A pril 2009 to N ovember 2010, 27 patients with advanced E wing's sarcoma who had progressive disease after the first‐line chemotherapy regimen of vincristine, dactinomycin and cyclophosphamide and ifosfamide and etoposide were retrospectively reviewed in this analysis. CTX was given (0.6 g/m 2 , i.v. push day 1) and HCPT (6 mg/m 2 , i.v. drip days 1–5) as second‐line chemotherapy every 3 weeks. The primary end‐point was overall response rate, the secondary end‐point included progression‐free, overall survival, disease control rate and toxicities. Results A total of 134 cycles were given, median four cycles per patient (range 2–6). Overall response rate was 30% and disease control rate was 82%, with two complete response (8%), six partial remission (22%) and 14 stable disease (52%). The median time to progression and overall survival time were 7 months (95% CI 3–10) and 11 months (95% CI 5–18), respectively. Major severe toxicities (grade 3 and 4) were: nausea/vomiting (17%), alopecia (17%); leukopenia (27%) in total cycles. Mild toxicities (grade 1 or 2) were leukopenia (73%), nausea/vomiting (83%), hepatic lesion (14%) and anemia (44%). Conclusion A CTX‐HCPT regimen can control disease progression effectively and the side effects can be tolerable for C hinese advanced E wing's sarcoma patients. Further assessment is necessary to confirm the safety and efficacy of this treatment.
Type of Medium:
Online Resource
ISSN:
1743-7555
,
1743-7563
DOI:
10.1111/ajco.2014.10.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2187409-8
Permalink